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Abstract: A set of structurally related O-methylated flavonoid natural products isolated from Senecio
roseiflorus (1), Polygonum senegalense (2 and 3), Bhaphia macrocalyx (4), Gardenia ternifolia (5), and Psiadia
punctulata (6) plant species were characterized for their interaction with human monoamine oxidases
(MAO-A and -B) in vitro. Compounds 1, 2, and 5 showed selective inhibition of MAO-A, while 4 and
6 showed selective inhibition of MAO-B. Compound 3 showed ~2-fold selectivity towards inhibition
of MAO-A. Binding of compounds 1–3 and 5 with MAO-A, and compounds 3 and 6 with MAO-B
was reversible and not time-independent. The analysis of enzyme-inhibition kinetics suggested a
reversible-competitive mechanism for inhibition of MAO-A by 1 and 3, while a partially-reversible
mixed-type inhibition by 5. Similarly, enzyme inhibition-kinetics analysis with compounds 3, 4, and 6,
suggested a competitive reversible inhibition of MAO-B. The molecular docking study suggested that
1 selectively interacts with the active-site of human MAO-A near N5 of FAD. The calculated binding
free energies of the O-methylated flavonoids (1 and 4–6) and chalcones (2 and 3) to MAO-A matched
closely with the trend in the experimental IC50′s. Analysis of the binding free-energies suggested
better interaction of 4 and 6 with MAO-B than with MAO-A. The natural O-methylated flavonoid
(1) with highly potent inhibition (IC50 33 nM; Ki 37.9 nM) and >292 fold selectivity against human
MAO-A (vs. MAO-B) provides a new drug lead for the treatment of neurological disorders.
Keywords: recombinant monoamine oxidase-A; monoamine oxidase-B; neurological disorder;
enzyme kinetics; molecular docking; inhibition activity; flavonoid
1. Introduction
Monoamine oxidases (EC.1.4.3.4; MAO-A and -B) are FAD-dependent enzymes that are responsible
for the metabolism of neurotransmitters such as dopamine, adrenaline, serotonin, and noradrenaline,
and also for the inactivation of exogenous arylalkyl amines [1–3]. Due to their vital role in
neurotransmitter metabolism, these enzymes signify attractive drug targets for the pharmacological
therapy of neurodegenerative diseases and neurological disorders [4–7]. Recent efforts toward the
Molecules 2020, 25, 5358; doi:10.3390/molecules25225358 www.mdpi.com/journal/molecules
Molecules 2020, 25, 5358 2 of 14
development of MAO inhibitors have been focused on selective, reversible MAO-A or MAO-B inhibitors.
The identification of MAO inhibitors could be helpful for numerous aspects of new drug discovery.
Selective MAO-A inhibitors are effective in the treatment of depression and anxiety [8–11]. By contrast,
MAO-B inhibitors are suitable for the treatment of the neurodegenerative diseases Alzheimer’s disease
and Parkinson’s disease [5,7,8,11,12]. Historically, monoamine oxidase inhibitors (MAOI’s) have been
used to treat neurological disorders including depression [10]. Presently, MAO-A inhibitors play
an important role in the control of neurological disorders, anxiety, and depression, while MAO-B
inhibitors could potentially be used as therapeutic agents for Parkinson’s and Alzheimer’s diseases [13].
Pharmacotherapeutic limitations and adverse effects of the currently available MAO inhibitor drugs
require the discovery of new MAO inhibitors with selective inhibition profiles and multi-target
neuropharmacological profiles [12]. Natural products provide useful sources for MAO inhibitors
combined with neuroprotective actions [3,14,15]. Several plant extracts and bioactive natural product
metabolites with catecholaminergic neuropharmacological properties [16] have shown promising
utility for the treatment of Alzheimer’s disease and Parkinson’s disease [17].
Recent studies from our lab have reported selective inhibition of MAO with flavonoid natural
products [18–20]. In continuation of these studies on selected classes of flavonoids as well as other related
published reports on various flavonoids [21,22], we have selected a series of methoxylated flavones
and chalcones from our repository for further evaluation to explore their activities. The structure of
chalcone is different from flavone/flavonol/flavanone, but they are biogenetically correlated. However,
from our previous studies on flavone/flavanone [18,19], and those reported for chalcones [23] as
valid MAO inhibitors, the difference in structures did not explain the structure–activity relationship
for the inhibition of MAO A/B. Therefore, we chose to study the MAO inhibitory activity of these
two types of flavonoids (flavone/flavonol and chalcone), including their docking studies. Therefore,
these studies were further extended to test a set of related O-methylated flavonoids isolated from
different plants, namely, Senecio roseiflorus (3,4′-di-O-methylkaempferol; 1) [24], Polygonum senegalense
(2′-hydroxy-4′,6′-dimethoxy-chalcone; 2 and 2′,4′-dihydroxy-6′-methoxy-chalcone; 3) [25],
Bhaphia macrocalyx (8-demethylsideroxylin; 4) [26] Gardenia ternifolia (4′-O-methylkaempferol; 5) [27],
and Psiadia punctulata (5,7-dihydroxy-2,3,4,5-tetramethoxyflavone; 6), [28] for experimental activities
against MAO-A and -B. The isolated compounds are all non-polar chalcones (di-O-methylated, 2, and 3)
and flavones exhibiting mono-O-methylation (4 and 5) or di-O-methylation (1) or tetra-O-methylation
(6). There was one (4) which even showed ring A C-methylation (4) (Figure 1). This study was also
extended to determine enzyme kinetics and the mechanism of inhibition of the compounds which
showed the best IC50 values in the recombinant human monoamine oxidases assays (MAO-A and
-B). Furthermore, molecular docking simulations were performed to understand the putative binding
modes of the best compounds to MAO-A and -B.
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2. Results
2.1. Isolation, Purification, and Characterization of O-Methylated Flavonoids
The O-methylated flavonoids reported in this paper were isolated from various plants,
using general methods reported earlier [25,27]. Aerial parts (leaves and branches) were dipped
in a non-polar solvent for short periods to wash off the exudates into the solvent (without affecting
cell vacuole compounds). The solvents used were normally medium polarity solvents such as
acetone or ethyl acetate. The solvent was removed using a rotary evaporator and the remaining solid
materials were subjected to column chromatography using silica gel as a stationary phase and eluting
with hexane/dichloromethane in a gradient fashion continuously increasing polarity followed by
dichloromethane/methanol. Compounds 1–6 were isolated from different plants, namely, S. roseiflorus
(1) [24], P. senegalense (2 and 3) [25], G. ternifolia (5) [27], P. punctulata (6) [28], and B. macrocalyx (4).
Compound 4 is the first report from the genus Baphia. The isolation of compound 4 was not reported
in the literature by us, therefore, its structure was determined using 1D and 2D NMR spectral data and
TOF-MS (see Material and Methods section for details).
2.2. Enzyme Inhibition and Kinetics Mechanism of MAO-A and -B with Compounds 1–6
The inhibition (IC50) of the MAO-A and -B enzymes by compounds 1–6 are shown in Table 1.
Compounds 1, 2, and 5 showed selective potent inhibition of MAO-A compared to compound 3,
which was potent at MAO-A but only slightly selective for MAO-A over -B. Compounds 4 and 6 were
more potent than 3 at MAO-B and were selective for MAO-B over -A.
Table 1. Inhibition of recombinant human MAO-A and MAO-B by a selected set of O-methylated
flavonoids 1–6. The results with significantly potent inhibition are presented in bold.
Compounds MAO-A IC50 (µM) a MAO-B IC50 (µM) a SI b SI c
1 0.033 ± 0.042 9.667 ± 2.309 0.0034 292.93
2 0.407 ± 0.075 5.933 ± 0.833 0.082 14.57
3 1.167 ± 0.513 2.700 ± 0.794 0.432 2.31
4 5.167 ± 1.106 0.800 ± 0.180 6.451 0.154
5 1.350 ± 0.198 >100 - >74.07
6 87.501 ± 3.536 0.875 ± 0.035 100.0 0.009
Clorgyline b 0.0065 ± 0.001 - - -
Deprenyl c - 0.043 ± 0.011 - -
a The IC50 values computed from the dose–response inhibition curves are mean ± S.D. of at least triplicate
observations. b SI Selectivity index: MAO-A IC50/MAO-B IC50. c Selectivity Index: MAO-A IC50 / MAO-B IC50.
bClorgyline and cL-deprenyl were used as positive controls for MAO-A and -B, respectively.
Furthermore, the MAO-A inhibition mechanisms of compounds 1–3 and 5 were studied,
using varying concentrations of kynuramine, a nonselective substrate, to investigate the nature
of inhibition of the enzymes. Based on dose–response inhibition results, at least two concentrations
of 1–3 and 5 were selected for the inhibition kinetics assay—one below and another above the IC50
value. Three sets of assays were completed at varying concentrations of the substrate for each
experiment, one control without inhibitor and the others with two different concentrations of the
inhibitor. The data were evaluated by double reciprocal Lineweaver-Burk plots for determination of
the Ki (i.e., inhibition/binding affinity) values. Binding of compounds 1–3 and 5, with human MAO-A,
yielded the Km value (i.e., the affinity of the substrate for the enzyme) as well as Vmax (maximum
enzyme activity) (Figure 2A–D). Ki values were computed from the double reciprocal plots (Table 2).
Binding of compounds 3, 4, and 6 to human MAO-B yielded the Km value (i.e., the affinity of the
substrate for the enzyme) as well as Vmax (maximum enzyme activity) (Figure 3A–C). Ki values were
computed from the double reciprocal plots (Table 2). Compounds 3, 4, and 6 showed inhibitory activity
of MAO-B with substantially high affinity (Ki = 1.242, 0.809, and 0.874 µM, respectively) (Table 2).
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Figure 2. Kinetics characteristics of the inhibition mechanism of recombinant human MAO-A by
compounds (A) 1; (B) 2; (C) 3; (D) 5; and (E) Clorgyline. Each point shows the mean value of
three observations.
Table 2. Inhibition/binding affinity constants (Ki) for inhibition of recombinant human MAO-A by
compounds 1–3 and 5 and of MAO-B by compounds 3, 4, and 6.
Compounds Monoamine Oxidase-A Monoamine Oxidase-B
Ki (µM) a Type of Inhibition Ki (µM) a Type of Inhibition
1 0.0379 ± 0.0008 Competitive/Reversible - -
2 0.339 ± 0.219 Competitive/Reversible - -
3 0.633 ± 0.107 Competitive/Reversible 1.242 ± 0.600 Competitive/Reversible
4 - - 0.809 ± 0.093 Mixed/Reversible
5 3.531 ± 0.265 Mixed/Partially Reversible - -
6 - - 0.874 ± 0.069 Competitive/Reversible
Clorgyline b 0.0018 ± 0.0003 Mixed/Irreversible - -
Deprenyl b - - 0.0101 ± 0.0034 Mixed/Irreversible
a The results are presented as the mean ± SD of three observations; b Clorgyline and l-deprenyl were used as
positive controls for MAO-A and -B, respectively.
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2.3. Binding and Time-Dependent Assays of MAO-A and -B with Compounds 1–6
The characteristics of binding of compounds 1–3 and 5 with MAO-A were investigated by
the equilibrium-dialysis assay. High concentrations of the compounds 1–3 and 5 (10.0, 25.0, 25.0,
and 100.0 µM, respectively) were incubated with the MAO-A enzyme for 20 min and the resulting
enzyme–inhibitor–complex preparation was dialyzed overnight against the 0.025 M phosphate buffer
(pH 7.4). The activities of the enzyme were analyzed before and after the dialysis (Figure 4). The binding
of compounds 1–3 with MAO-A was reversible and compound 5 showed partial reversibility (Table 2).
Incubation of MAO-B with compounds 3, 4, and 6 (50.0, 50.0, and 50.0 µM, respectively) produced
more than 60% inhibition of activity, and 80% of the activity of the enzyme was recovered after
dialysis (Figure 5). Thus, the binding of compounds 3, 4, and 6 with MAO-B was reversible (Table 2).
The selective MAO-B inhibitor deprenyl was confirmed to bind irreversibly with the enzyme (Table 2).
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show time-dependent i hibition of MAO-B (Figure 6B). For validation, we have ru - and -B
standards simultaneously for the time-dependent assay.
Molecules 2020, 25, x FOR PEER REVIEW 6 of 14 
 
 
Figure 5. Binding modes of compounds 3 (50.0 μM), 4 (50.0 μM), 6 (50.0 μM) and L-deprenyl (0.500 
μM) with MAO-B. 
Further investigation of the time dependence of the assay showed that the inhibition of MAO-A 
by compounds 1–3 and 5 was not time-dependent (Figure 6A). The compounds 3, 4, and 6 also did 
not show time-dependent inhibition of MAO-B (Figure 6B). For validation, we have run MAO-A and 





Figure 6. (A) Time-dependent inhibitio  of r combinant human MAO-A by compound  1 (0.20 μM), 
2 (1.6 μM), 3 (3.0 μM), 5 (16.0 μM) and L-deprenyl (0.010 μM). The remaining activity was expressed 
as % of initial activity. Each point represents the mean ± S.D. of triplicate values. (B) Time-dependent 
inhibition of recombinant human MAO-B by compounds 3 (3.0 μM), 4 (1.0 μM), 6 (2.0 μM) and L-
deprenyl (0.070 μM). The remaining activity was expressed as % of the initial activity. Each point 
represents the mean ± S.D. of triplicate values. 
2.4. Computational Analysis of Enzyme–Inhibitor Interactions 
A molecular docking study was performed to understand the binding pose and interaction 
profiles of compounds 1–6 to MAO-A and -B. h ӧdi ger’s I duc d-Fit docking rotocol was 
adopted to onsider the optimal geometry of the protein–ligand complex after conformational 
changes induced by the bou d ligand. The GlideScores and binding free-energies of compoun s 1–6 
in the active sites of the hMAO-A and hMAO-B X-ray crystal structures are presented in Table 3. The 
docking protocol used in this study was validated by self- or native-docking. The native ligands, 
harmine and pioglitazone, were extracted from the X-ray structures of MAO-A and -B, respectively, 
and docked into their corresponding protein models. The calculated RMSD between the docked and 
experimental poses were found to be identical <0.6 Å , which verified the suitability of the docking 
method for the current study. The putative binding mode and interactions of the best compounds 
with the X-ray crystal structures of MAO-A and -B are presented in Figure 7. The calculated binding 
free energies vary between 28–76 kcal/mol against MAO-A and -B. Since some of the measured Ki 
values are in the micromolar range, the binding affinities should be somewhere around 6–10 
Figure 6. (A) Time-dependent inhibition of recombinant human MAO-A by compounds 1 (0.20 µM),
2 (1.6 µ ), 3 ( . µ , . µ l- e renyl (0.010 µM). The remaining activity was xpressed as
% of initial activity. Each point represents the mean ± S. . i li l . ( ) Ti e-dependent
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l-deprenyl (0. 70 µM). The remai ing activity was expressed as % of the initial activity. Each point
represents the ean ± S.D. of triplicate values.
2.4. Computational Analysis of Enzyme–Inhibitor Interactions
A molecular docking study was performed to understand the binding pose and interaction profiles
of compounds 1–6 to MAO-A and -B. Schrödinger’s Induced-Fit docking protocol was adopted to
consider the optimal geometry of the protein–ligand complex after conformational changes induced
by the bound ligand. The GlideScores and binding free-energies of compounds 1–6 in the active
sites of the hMAO-A and hMAO-B X-ray crystal structures are presented in Table 3. The docking
protocol used in this study was validated by self- or native-docking. The native ligands, harmi e and
pioglitazone, were extracted from he X-ray structures of MAO-A and -B, respectively, and docked
into their corresponding pro ein models. The calculated RMSD between the docked and ex erimental
poses were found to be identical <0.6 Å, which verified the suitability of the docking method for the
current study. The putative binding mode and interactions of the best compounds with the X-ray
crystal structures of MAO-A and -B are presented in Figure 7. The calculated binding free energies
vary between 28–76 kcal/mol against MAO-A and -B. Since some of the measured Ki values are in the
micromolar range, the binding affinities should be somewhere around 6–10 kcal/mol. This is a known
limitation of the employed computations, which are useful not on an absolute scale but in relative
Molecules 2020, 25, 5358 7 of 14
terms among structurally similar ligands, which is the focus here Compound 1 exhibited a strong
binding affinity to the MAO-A receptor in terms of GlideScore and binding free energy (∆G = −57.522
kcal/mol) compared to the other compounds. The p-methoxy phenyl at the C-2 position (Ring-B)
of 1 showed π–π stacking with Phe208 and was surrounded by an array of hydrophobic residues,
including Leu97, Phe108, Ala111, Ile180, and Ile325. The hydroxyl at C-5 of ring A formed H-bonding
with N5 and C=O of FAD and the hydroxyl at C-7 of ring A exhibited water-mediated H-bonding
with Tyr444. In addition, Ring A was surrounded by strong hydrophobic residues Tyr69, Tyr197,
Tyr407, and Tyr444. The best GlideScore and binding free energy matched well with the experimental
binding affinity of 1. Interestingly, 1 and 5 had the difference of –OCH3 and –OH, respectively, at the
C-3 position of ring C but had significant differences in their MAO-A binding affinity. Our docking
results also predicted relatively poor GlideScores and binding free energy for compound 5 compared
to compound 1. After careful observation, we have found that the methoxy group at C-3 of 1 exhibited
strong hydrophobic interactions with Ile335 and Leu337 compared to the hydroxyl group at C-3 of
5. Compounds 1 and 5 have very similar poses; however, compound 1 slightly shifted towards FAD
(~1.5 Å) compared to 5. In addition, the hydroxyl at Ring A of 5 did not show any H-bonding with
FAD, further helping to explain the poorer binding affinity of compound 5 for MAO-A. Interestingly,
compound 1 showed better GlideScore and binding free energy for MAO-B than for MAO-A (see
Table 3); however, its best-ranked docking pose left it 15 Å away from the N5 of FAD, which apparently
is an unrealistic docking prediction. In the search for an alternative pose for 1 to MAO-B, we found a
pose in which 1 fit into the active site of MAO-B (near N5 of FAD) with a GlideScore of −9.705 kcal/mol,
and that is the one reported in Table 3. The substitutions of acetyl (-CH3CO) and methylsulfone
(-SO2CH3) at the C-3 and C-4′ of Ring B of 1 are predicted to enhance the affinity towards MAO-A.
The poly-substituted methoxy group at Ring B caused a loss of binding affinity towards MAO-A but
submicromolar activity towards MAO-B.
Table 3. GlideScores and binding free energies of compounds 1–6 to MAO-A and -B.
Compounds Experimental IC50 (µM)
a GlideScore (kcal/mol) Binding Free-Energy (kcal/mol)
MAO-A MAO-B MAO-A MAO-B MAO-A MAO-B
1 0.033 ± 0.04 9.667 ± 2.309 −11.667 −10.028 b −57.522 −76.353 b
2 0.407 ± 0.075 5.933 ± 0.833 −10.686 −9.999 −47.724 −28.119
3 1.167 ± 0.513 2.700 ± 0.794 −9.951 −10.579 −37.683 −51.309
4 5.167 ± 1.106 0.800 ± 0.180 −9.664 −10.225 −35.043 −53.574
5 1.350 ± 0.198 >100 −10.567 ND c −47.035 ND c
6 87.501 ± 3.536 0.875 ± 0.035 −7.239 −11.191 −34.651 −68.053
a The data are mean ± SD of three observations.; b The best pose is 15 Å away from the N5 of FAD (substrate active
site); the numbers given here are for an alternate pose (see text); c ND = Not determined.
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crystal structures of MAO-A and -B. (A) 1 (C magenta, stick model) and 5 (C cyan, stick model) with
MAO-A, (B) 2 (C light green, stick model) with MAO-A, (C) 4 (C blue, stick model) and 6 (C orange,
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green), and the important residues of MAO-A and MAO-B (C gray) are also shown. The black dashed
lines represent H-bonding.
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The next structural category, chalcone, represented by compounds 2 and 3, was analyzed.
Compound 2 showed the more negative binding free energy (∆G = −47.724 kcal/mol) compared to
compound 3 (∆G = −37.683 kcal/mol) for binding to MAO-A, and these data match closely with
the experimental binding affinities (cf. Table 1). The only structural difference between compounds
2 and 3 involves C-4′ carrying methoxy and hydroxyl moieties, respectively. The docked pose of
2 in the MAO-A receptor showed H-bonding of its hydroxyl moiety at C-6′ and its C-1 carbonyl
(water-mediated H-bonding) with Asn181. In addition, the oxygen of the methoxy at C-4′ exhibited
water-mediated H-bonding with Gln215 and Tyr444. The major difference of binding free energy
between 2 and 3 was because of an additional strong hydrophobic interaction (CH . . . C, C . . . C,
and CH . . . π) of the C-4′ methoxy group of 2 with Tyr69, Phe352, and Tyr407, respectively.
The GlideScores and binding free energies of the flavonoids 4 and 6 showed a better binding
affinity for interaction with MAO-B (4: GlideScore = −10.225 kcal/mol, ∆G = −53.574 kcal/mol and
6: GlideScore = −11.191 kcal/mol, ∆G = −68.053 kcal/mol) than with MAO-A. Compounds 4 and 6
docked in a very similar orientation and showed H-bonding interactions between their C-4 carbonyl
and Cys172. In addition, the C-5 hydroxyl of 4 and 6 showed water-mediated H-bonding with Tyr188,
and Gln206 and the C-4 hydroxyl had direct hydrogen-bonding with the backbone carbonyl of Cys172.
Ring A had an orientation towards the isoalloxazine ring of FAD and was surrounded by an array
of hydrophobic residues, including Tyr60, Phe343, Tyr398, and Tyr435. Furthermore, Ring B was
surrounded by hydrophobic residues Leu164, Leu167, Phe168, Ile199, Ile316, and Tyr326 (including
π–π stacking for Tyr326). Overall, the docking results of compounds 1–6 were in good agreement with
the experimental binding data for MAO-A and -B.
3. Discussion
The molecules with reversible selective inhibition of MAO-A or MAO-B have therapeutic potential
for the treatment of neurological and psychiatric disorders, especially caused due to depletion of
neurotransmitter biogenic amines [9,29,30]. Previous studies from our lab have reported selective
inhibition of human MAO-B with flavonoid natural products [18–20]. A recent study has also
reported MAO-A and MAO-B inhibition activity by acacetin 7-O-(6-O-malonylglucoside), a derivative
of acacetin isolated from Agastache rugosa plant leaves [31]. The follow-up studies presented here
with a select set of O-methylated flavonoids (1–6) identified MAO inhibitors selective against both
MAO-A (1–3 and 5) and MAO-B (4 and 6). Compounds 1–3 interact with MAO-A through reversible
binding as assessed by the enzyme–inhibitor complex equilibrium dialysis assay, while the binding
of compound 5 with MAO-A was partially reversible. The inhibition of MAO-A by compounds 1–3
and 5 was not time-dependent. A recent paper reported MAO-A and -B inhibition activity by natural
constituent acacetin 7-O-(6-O-malonylglucoside) that was isolated and purified from Agastache rugosa
plant leaves [32]. Compounds 3, 4, and 6 also interact with MAO-B reversibly, as assessed by the
enzyme–inhibitor complex equilibrium dialysis assay, and the inhibition was not time-dependent.
Computational analysis of the binding of 1–6 with human MAO-A and -B revealed the putative
binding mode and interaction profiles of the compounds with MAO-A and -B. Among all the
O-methylated flavonoids, 1 showed the strongest computed interaction with MAO-A and exhibited
H-bonding with N5 and C=O of FAD through the hydroxyl at C-5 of Ring A. In addition, the hydroxyl
at C-7 of Ring A also exhibited water-mediated H-bonding with Tyr444. 1 also showed π–π interactions
with Phe208 and was surrounded by an array of hydrophobic residues. On the other hand, 4 and 6
showed strong interactions with MAO-B and shared an identical binding mode with MAO-B. This study
suggests that it would be worthwhile to perform further evaluation of compounds 1–6 including
considering the effects of their MAO-A and -B inhibitory actions in experimental animal models of
neurological and/or neurodegenerative disorders.
The O-methylated flavonoids are predominant bioactive secondary metabolites present in several
plants [32]. The O-methylated flavonoids are generated in plants through the action of specific
O-methyltransferase (OMT) enzymes [33]. O-methylation changes the solubility of flavonoids and
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improves bioactive properties compared to their non-methylated counterparts [34]. The natural product
O-methylated flavonoid 3,4′-di-O-methylkaempferol (1) isolated from S. roseiflorus was identified as a
highly potent inhibitor of human MAO-A with IC50 and Ki values of 33 nM and 37.8 nM, respectively.
The metabolite 1 was more than 292-fold selective for MAO-A over MAO-B. The compound formed a
reversible enzyme–inhibitor complex and was had a very low Ki for MAO-A. With its highly potent
MAO-A inhibition and extraordinary selectivity for human MAO-A over MAO-B, 1 is worth optimizing
further as a new-drug lead and merits advancement to preclinical evaluations regarding utility for the
treatment of neurological and psychiatric disorders.
4. Materials and Methods
4.1. Enzymes
Recombinant human monoamine oxidase (rhMAO-A and -B) enzymes were purchased from BD
Biosciences (Bedford, MA, USA). Kynuramine, clorgyline, deprenyl, and DMSO were obtained from
Sigma Chemical (St Louis, MO, USA).
4.2. Isolation and Identification of Compounds 1–6
Compounds 1–3, 5, and 6 (Figure 1) were isolated and characterized by 1H and 13C-NMR spectra
from Senecio roseiflorus (1), Polygonum senegalense (2 and 3), Gardenia ternifolia (5), and Psiadia punctulata
(6) plant species collected from Kenya [24,25,27,28] (vide supra). In addition, compound 4 was isolated
from the leaves of B. macrocalyx, collected from Southern Tanzania (Mikindaniya Leo village). A voucher
specimen (FMM 3579) was deposited at the Herbarium of the Department of Botany, University of Dar
es Salaam, Tanzania. The dried pulverized plant material (5 kg) underwent sequential cold solvent
extraction with hexane, EtOAc, and finally MeOH, each soaked in each solvent for 24 h, then the
solvents were evaporated with a rotavap yielding hexane, EtOAc, and MeOH extracts (100, 300 and
200 g, respectively). Column chromatography of EtOAc extract (70 g) on silica gel (Merck silica gel 60;
0.40–0.63 mm) eluting with a hexane-DCM gradient, from 100% hexane to 100% DCM and finally in
methanol afforded 10 fractions. The fractions eluting with hexane: DCM (3:7) afforded compounds 4
(8-desmethylsideroxylin, 13.2 mg); obtained as yellow needles, mp 275–277 ◦C (Lit. 275–277 ◦C; ESI MS
(TOF +ve, Finnigan Mat SSQ 7000): m/z 299.1 ([M+H]+, C17H14O5+H) 1H-NMR (600 MHz, Avance
Bruker): 6.82, s, 1H (H-3), 6.82, s, 1H (H-8), 7.95, dd, 2H, J = 2.4, 9.0 Hz (H-2′/6′), 6.93, dd, 2H, J = 2.4,
9.0 Hz (H-3′/5′), 1.98, s, 3H (C-6-Me), 3.90, s, 3H (C-7-OMe), 13.08, s, 1H (C-5-OH), 1H-NMR spectra
was in agreement with those reported in the literature); 13C-NMR: 161.3 (C-2), 103.1 (C-3), 182.0 (C-4),
104.4 (C-4a), 157.5 (C-5), 107.6 (C-6), 163.1 (C-7), 90.4 (C-8), 155.5 (C-8a), 121.2 (C-1′), 128.6 (C-2′/6′),
116.2 (C-3′/5′),163.9 (C-4′), 7.4 (CH3 at C-6), 56.3 (OCH3 at C-7). All NMR spectra of 1–6 are provided
in Supplementary Information.
4.3. MAO Inhibition Assay
In this study, we have investigated the effect of the isolated constituents (1–6) on human
recombinant MAO-A and -B. The kynuramine oxidation deamination assay was performed in 96-well
plates as previously reported, with modification [18,35]. A fixed concentration of kynuramine substrate
and varying concentrations of test compounds or inhibitor were used to determine the IC50 values.
Kynuramine concentrations for MAO-A and -B were 80 µM and 50 µM, respectively. The concentrations
of compounds 1–6 varied from 0.001 µM to 100 µM for the rhMAO-A and -B enzyme activity inhibition.
The test compounds 1–6 were dissolved in DMSO, diluted in the buffer solution just before the assay,
and pre-incubated with the enzyme for 10 min at 37 ◦C. The final concentration of DMSO in the
enzyme-assay reaction mixtures did not exceed 1%. The enzymatic reactions were initiated by the
addition of MAO-A (5 µg/mL) or -B (12.5 µg/mL), and incubated for 20 min at 37 ◦C. The enzyme
reactions were terminated by the addition of 78 µL of 2N NaOH. The formation of 4-hydroxyquinoline
(the enzyme reaction end product) was recorded fluorometrically on a SpectraMax M5 fluorescence plate
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reader (Molecular Devices, Sunnyvale, CA, USA) with an excitation (320 nm) and emission (380 nm)
wavelength, using the Soft MaxPro-6 program. The inhibition effects of enzyme activity were calculated
as the percent of product formation compared to the corresponding controls (enzyme–substrate
reaction) without inhibitors. The assay controls, to define the interference of the test compounds with
the fluorescence measurements, were set up simultaneously, and the enzyme or the substrate was
added after stopping the reaction.
4.4. Determination of IC50 Values
The enzyme assays were performed at a fixed concentration of the substrate kynuramine (80 µM
for MAO-A and 50 µM for MAO-B) and different concentrations of the test compounds (1–6).
The dose–response enzyme-inhibition curves were generated using Microsoft® Excel and the IC50
values were computed with XLfit®.
4.5. Enzyme Kinetics and Mechanism Studies
For determination of the binding affinity of the inhibitor (Ki) to MAO-A and -B, the enzyme assays
were carried out at different concentrations of kynuramine substrate (1.90 µM to 500 µM) and varying
concentrations of the inhibitors/compound. The flavonoids (1–6) were tested at 0.030–0.100µM for MAO-A
and 0.100–0.500 µM for -B. The controls without inhibitor were also run simultaneously. The results were
analyzed by SigmaPlot version 10 using standard double reciprocal Lineweaver-Burk plots for computing
Km and Vmax values, which were further analyzed to determine the Ki values [18,36,37].
4.6. Analysis of Binding of Inhibitor with The Enzymes
Enzyme-inhibitors mostly produce inhibition of the target enzyme through the formation of an
enzyme–inhibitor complex. The formation of the enzyme–inhibitor complex may be accelerated in
the presence of a high concentration of the test inhibitor. The property of binding of test compounds
to MAO-A or -B was determined by the formation of the enzyme–inhibitor complex by incubation
of the enzyme with a high concentration of the test compound. This was followed by extensive
equilibrium dialysis of the enzyme–inhibitor complex. Recovery of catalytic activity of MAO-A and -B
was determined before and after the dialysis. The MAO-A enzyme (0.2 mg/mL protein) was incubated
with each test compound: 1 (10.0 µM), 2 (25.0 µM), 3 (25.0 µM), 5 (100.0 µM) and clorgyline (0.100 µM),
in 1 mL of potassium phosphate buffer (100 mM, pH 7.4). After 20 min incubation at 37 ◦C, the reaction
was stopped by chilling the tubes in an ice bath. Similarly, the MAO-B enzyme (0.2 mg/mL protein) was
incubated with each test compound: 3 (50.0 µM), 4 (50.0 µM), 6 (50.0 µM), and deprenyl (0.500 µM),
in 1.0 mL potassium phosphate buffer (100 mM, pH 7.4). After 20 min incubation at 37 ◦C, the reaction
was stopped by chilling the tubes in an ice bath. All the samples with enzyme–inhibitor complex
were individually dialyzed against potassium phosphate buffer (25 mM; pH 7.4) at 4 ◦C for 16–18 h
(including three buffer changes). The control enzyme (without inhibitor) was also run through the
same procedure and the activity of the enzyme was determined before and after the dialysis [36].
4.7. Time-Dependent Inhibition of the Enzyme
To investigate if the binding of the inhibitor with MAO-A and -B followed time-dependent
inhibition kinetics, the enzyme was pre-incubated with the inhibitor for different time periods
(0–15 min). The compound concentrations used to test time-dependent inhibition were: 1 (0.20 µM),
2 (1.6µM), 3 (3.0 µM) and 4 (16.0µM) and clorgyline (0.010µM), with MAO-A (5.0µg/mL). The inhibitor
concentrations used to test time-dependent inhibition were: 3 (3.0 µM), 4 (1.0 µM), 6 (2.0 µM),
and deprenyl (0.070 µM), with MAO-B (12.5 µg/mL). The controls without inhibitors were also run
simultaneously. The activities of the MAO-A and -B enzymes were determined as described above and
the percentage of enzyme activity remaining was plotted against the pre-incubation time to determine
time-dependent inhibition.
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4.8. Computational Analysis of The Interaction of Test Compounds with MAO-A or -B
The X-ray crystal structures of MAO-A (PDB ID: 2Z5X) and MAO-B (PDB ID: 4A79 [38] were
directly imported from the Protein Data Bank website (https://www.rcsb.org) to Maestro [39] using
the Protein Preparation Wizard module of the Schrödinger software (Cambridge, MA, USA) [40].
We followed a similar method and protocol for docking as previously described [19]. The protein
structures of MAO-A and -B were each used as monomers in the docking study. In brief, these proteins
were prepared by adding hydrogens, adjusting bond orders, adding missing side chains, setting the
proper ionization states at pH 7.4, refining overlapping atoms, and making H-bond assignments
using PROPKA at pH 7.0. The water molecules beyond 5 Å from the co-crystallized ligands were
deleted and the protonation states of the co-crystallized ligands were generated using Epik at pH 7.4.
During the refinement process, water molecules with fewer than two H-bonds to non-waters were also
removed and, finally, restrained minimization of hydrogens only was performed using the Optimized
Potentials for Liquid Simulations 3 (OPLS3) force field [41]. The cofactor FAD was not removed
during protein preparation and docking. The 2D structures of compounds 1–6 were sketched in the 2D
sketcher module of Maestro, prepared, and energy-minimized at a physiological pH of 7.4 using the
LigPrep module [42] of the Schrödinger software. The compounds were docked as neutral molecules.
The OPLS3 force field was used for protein and ligand preparation, and docking. The active sites
of the MAO-A and -B proteins were generated using the centroid of the co-crystallized ligands of
2Z5X and 4A79, respectively. The Induced Fit docking [43] protocol was used for the docking of
compounds 1–6. The standard precision (SP) docking method was applied during the initial docking
stages. In the initial Glide docking, the receptor and the ligand were “softened” by van der Waals
radii scaling. The scaling factor was chosen to be 0.50 for both the ligand and the receptor to permit
enough flexibility for the ligand to dock in the best poses. The “trim-side chains” option was not used
in this study. The maximum number of poses was chosen to be 20. In the next step, residues that are
within 5 Å of the active site (ligand) were refined using the “Prime Refinement” Table In the final step,
a threshold of 30 kcal/mol was used to redock the best structure, for eliminating high-energy structures
from the Prime refinement step. The top 20 poses were kept for analysis and the best poses were
selected based on IFD scores and visual inspection of protein–ligand interactions. The best docking
poses were subjected to binding free-energy calculations using the Prime MM-GBSA module of the
Schrödinger software allowing protein flexibility within 5 Å of the ligand. Only protein side-chains
were minimized during the calculations. Finally, the Maestro Version 11.5 molecular graphics system
was used to create all the computationally derived figures.
5. Conclusions
Screening of a selected set of O-methylated flavonoid constituents isolated from Senecio roseiflorus,
Bhaphia macrocalyx, Polygonum sengalense, Psiadia punctulata, and Gardenia ternifolia identified compounds
1–3 and 5 as potent and selective inhibitors of human MAO-A, relative to MAO-B, and compounds
4 and 6 as selective inhibitors of human MAO-B. Further investigations suggested compounds
1–3 as reversible and competitive inhibitors and compound 5 as a partially reversible mixed-type
inhibitor of MAO-A and compounds 3, 4, and 6 as reversible and competitive inhibitors of MAO-B.
The computational results for compounds 1–6 were in good agreement with the experimental binding
data for MAO-A and -B. The compounds 1 and 6 with high potency and selectivity of inhibition against
MAO-A and MAO-B, respectively, may be promising new drug leads for further development as
therapeutic treatment of neurological disorders, depression, Alzheimer’s disease, and Parkinson’s
disease. It is important to mention that the flavonoid scaffold possesses promiscuous biological activity
that may be due to inherent structural features. For this reason, they should be treated with caution as
lead compounds for drug development.
Supplementary Materials: All NMR spectra of compounds 1–6 are provided as Supplementary Information.
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